• Genetic TherapyEnrolling

  Study to evaluate KB407 in adults with cystic fibrosis , protocol number Krystal Biotech KB407-02 - Cohort 4

  This study will evaluate safety and tolerability of nebulized KB407, a gene therapy intended to deliver a new, correct copy of the CFTR gene (DNA) to cells in adults with cystic fibrosis.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 85%

  • Number of Visits:

    28

  • Length of Participation:

    6 months

• Genetic TherapyEnrolling

  Study of ARCT-032 in adults with cystic fibrosis who are not on CFTR modulator therapy. , protocol number Arcturus ARCT-032-02 Cohort 4

  This study will test the safety, tolerability and effectiveness of ARCT-032, a nebulized therapy intended to deliver a new, correct copy of CFTR messenger RNA (mRNA) to cells.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    45 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    24 weeks

• Genetic TherapyEnrolling

  Study of 4D-710 in Adults with Cystic Fibrosis , protocol number 4DMT 4D-710-C001 (Part 1 and 2)

  This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    22

  • Length of Participation:

    1 years

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.